Genes associated with Alzheimer's disease: an overview and current status

Mohan Giri, Man Zhang, Yang Lü, Mohan Giri, Man Zhang, Yang Lü

Abstract

Alzheimer's disease (AD) is a progressive, neurodegenerative disease and the most common form of dementia in elderly people. It is an emerging public health problem that poses a huge societal burden. Linkage analysis was the first milestone in unraveling the mutations in APP, PSEN1, and PSEN2 that cause early-onset AD, followed by the discovery of apolipoprotein E-ε4 allele as the only one genetic risk factor for late-onset AD. Genome-wide association studies have revolutionized genetic research and have identified over 20 genetic loci associated with late-onset AD. Recently, next-generation sequencing technologies have enabled the identification of rare disease variants, including unmasking small mutations with intermediate risk of AD in PLD3, TREM2, UNC5C, AKAP9, and ADAM10. This review provides an overview of the genetic basis of AD and the relationship between these risk genes and the neuropathologic features of AD. An understanding of genetic mechanisms underlying AD pathogenesis and the potentially implicated pathways will lead to the development of novel treatment for this devastating disease.

Keywords: Alzheimer’s disease; amyloid precursor protein; biological pathways; genome-wide association studies; neuropathology; presenilin 1; presenilin 2.

Figures

Figure 1
Figure 1
Major pathways involved in AD and affected genes. Abbreviation: AD, Alzheimer’s disease.

References

    1. Alzheimer’s Disease International Consortium [webpage on the Internet] World Alzheimer Report 2015. [Accessed April 11, 2016]. Available from: .
    1. Blennow K, de Leon MJ, Zetterberg H. Alzheimer’s disease. Lancet. 2006;368(9533):387–403.
    1. Gatz M, Reynolds CA, Fratiglioni L, et al. Role of genes and environments for explaining Alzheimer disease. Arch Gen Psychiatry. 2006;63(2):168–174.
    1. Bu G. Apolipoprotein E and its receptors in Alzheimer’s disease: pathways, pathogenesis and therapy. Nat Rev Neurosci. 2009;10(5):333–344.
    1. Huang Y, Mucke L. Alzheimer mechanisms and therapeutic strategies. Cell. 2012;148(6):1204–1222.
    1. Naj AC, Jun G, Beecham GW, et al. Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer’s disease. Nat Genet. 2011;43(5):436–441.
    1. Seshadri S, Fitzpatrick AL, Ikram MA, et al. Genome-wide analysis of genetic loci associated with Alzheimer disease. JAMA. 2010;303(18):1832–1840.
    1. Bertram L. Next generation sequencing in Alzheimer’s disease. Methods Mol Biol. 2016;1303:281–297.
    1. Tanzi RE, Bertram L. Twenty years of the Alzheimer’s disease amyloid hypothesis: a genetic perspective. Cell. 2005;120(4):545–555.
    1. Verghese PB, Castellano JM, Holtzman DM. Apolipoprotein E in Alzheimer’s disease and other neurological disorders. Lancet Neurol. 2011;10(3):241–252.
    1. Hattersley AT, McCarthy MI. A question of standards: what makes a good genetic association study? Lancet. 2005;366(9493):1315–1323.
    1. Karch CM, Cruchag C, Goate AM. Alzheimer’s disease genetics: from the bench to the clinic. Neuron. 2014;83(1):11–26.
    1. Cruts M, Theuns J, Van Broeckhoven C. Locus-specific mutation databases for neurodegenerative brain diseases. Hum Mutat. 2012;33(9):1340–1344.
    1. Yoshikai S, Sasaki H, Doh-ura K, Furuya H, Sakaki Y. Genomic organization of the human amyloid beta-protein precursor gene. Gene. 1990;87(2):257–263.
    1. Thinakaran G, Koo EH. Amyloid precursor protein trafficking, processing and function. J Biol Chem. 2008;283(44):29615–29619.
    1. Bekris LM, Yu CE, Bird TD, Tsuang DW. Genetics of Alzheimer disease. J Geriatr Psychiatry Neurol. 2010;23(4):213–227.
    1. Guerreiro RJ, Gustafson DR, Hardy J. The genetic architecture of Alzheimer’s disease: beyond APP, PSENs and APOE. Neurobiol Aging. 2012;33(3):437–456.
    1. De Jonghe C, Esselens C, Kumar-Singh S, et al. Pathogenic APP mutations near the gamma-secretase cleavage site differentially affect Abeta secretion and APP C-terminal fragment stability. Hum Mol Genet. 2001;10(16):1665–1671.
    1. Mullan M, Crawford F, Axelman K, et al. A pathogenic mutation for probable Alzheimer’s disease in the APP gene at the N-terminus of β-amyloid. Nat Genet. 1992;1(5):345–347.
    1. Prasher VP, Farrer MJ, Kessling AM, et al. Molecular mapping of Alzheimer-type dementia in Down’s syndrome. Ann Neurol. 1998;43(3):380–383.
    1. Goate A, Chartier-Harlin MC, Mullan M, et al. Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer’s disease. Nature. 1991;349(6311):704–706.
    1. Nilsberth C, Westlind-Danielsson A, Eckman CB, et al. The ‘Arctic’ APP mutation (E693G) causes Alzheimer’s disease by enhanced Abeta protofibril formation. Nat Neurosci. 2001;4(9):887–893.
    1. Kamino K, Orr HT, Payami H, et al. Linkage and mutational analysis of familial Alzheimer disease kindreds for the APP gene region. Am J Hum Genet. 1992;51(5):998–1014.
    1. Hendriks L, van Duijn CM, Cras P, et al. Presenile dementia and cerebral haemorrhage linked to a mutation at codon 692 of the beta-amyloid precursor protein gene. Nat Genet. 1992;1(3):218–221.
    1. Jonsson T, Atwal JK, Steinberg S, et al. A mutation in APP protects against Alzheimer’s disease and age-related cognitive decline. Nature. 2012;488(7409):96–99.
    1. Esler WP, Wolfe MS. A portrait of Alzheimer secretases – new features and familiar faces. Science. 2001;293(5534):1449–1454.
    1. Steiner H. Uncovering gamma-secretase. Curr Alzheimer Res. 2004;1(3):175–181.
    1. Steiner H, Revesz T, Neumann M, et al. A pathogenic presenilin-1 deletion causes aberrant Abeta 42 production in the absence of congophilic amyloid plaques. J Biol Chem. 2001;276(10):7233–7239.
    1. Takao M, Ghetti B, Hayakawa I, et al. A novel mutation (G217D) in the Presenilin 1 gene (PSEN1) in a Japanese family: presenile dementia and parkinsonism are associated with cotton wool plaques in the cortex and striatum. Acta Neuropathol. 2002;104(2):155–170.
    1. Verkkoniemi A, Kalimo H, Paetau A, et al. Variant Alzheimer disease with spastic paraparesis: neuropathological phenotype. J Neuropathol Exp Neurol. 2001;60(5):483–492.
    1. Breyhan H, Wirths O, Duan K, Marcello A, Rettig J, Bayer TA. APP/PS1KI bigenic mice develop early synaptic deficits and hippocampus atrophy. Acta Neuropathol. 2009;117(6):677–685.
    1. Pigino G, Morfini G, Pelsman A, Mattson MP, Brady ST, Busciglio J. Alzheimer’s presenilin 1 mutations impair kinesin-based axonal transport. J Neurosci. 2003;23(11):4499–4508.
    1. Wakabayashi T, De Strooper B. Presenilins: members of the gamma-secretase quartets, but part-time soloists too. Physiology (Bethesda) 2008;23(4):194–204.
    1. Jayadev S, Leverenz JB, Steinbart E, et al. Alzheimer’s disease phenotypes and genotypes associated with mutations in presenilin 2. Brain. 2010;133(4):1143–1154.
    1. Park MH, Choi DY, Jin HW, et al. Mutant presenilin 2 increases β-secretase activity through reactive oxygen species-dependent activation of extracellular signal-regulated kinase. J Neuropathol Exp Neurol. 2012;71(2):130–139.
    1. Bentahir M, Nyabi O, Verhamme J, et al. Presenilin clinical mutations can affect gamma-secretase activity by different mechanisms. J Neurochem. 2006;96(3):732–742.
    1. Harold D, Abraham R, Hollingworth P, et al. Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer’s disease. Nat Genet. 2009;41(10):1088–1093.
    1. Lambert JC, Ibrahim-Verbaas CA, Harold D, et al. European Alzheimer’s Disease Initiative (EADI) Genetic and Environmental Risk in Alzheimer’s Disease. Alzheimer’s Disease Genetic Consortium. Cohorts for Heart and Aging Research in Genomic Epidemiology Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer’s disease. Nat Genet. 2013;45(12):1452–1458.
    1. Bertram L, Lange C, Mullin K, et al. Genome-wide association analysis reveals putative Alzheimer’s disease susceptibility loci in addition to APOE. Am J Hum Genet. 2008;83(5):623–632.
    1. Solomon A, Kivipelto M, Wolozin B, Zhou J, Whitmer RA. Midlife serum cholesterol and increased risk of Alzheimer’s and vascular dementia three decades later. Dement Geriatr Cogn Disord. 2009;28(1):75–80.
    1. Corder EH, Saunders AM, Strittmatter WJ, et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer’s disease in late onset families. Science. 1993;261(5123):921–923.
    1. Saunders AM, Strittmatter WJ, Schmechel D, et al. Association of apolipoprotein E allele epsilon 4 with late-onset familial and sporadic Alzheimer’s disease. Neurology. 1993;43(8):1467–1472.
    1. Saunders AM. Apolipoprotein E and Alzheimer disease: an update on genetic and functional analyses. J Neuropathol Exp Neurol. 2000;59(9):751–758.
    1. Roses AD. Apolipoprotein E alleles as risk factors in Alzheimer’s disease. Annu Rev Med. 1996;47:387–400.
    1. Mahley RW, Weisgraber KH, Huang Y. Apolipoprotein E: structure determines function, from atherosclerosis to Alzheimer’s disease to AIDS. J Lipid Res. 2009;50(suppl):S183–S188.
    1. Herz J, Chen Y, Masiulis I, Zhou L. Expanding functions of lipoprotein receptors. J Lipid Res. 2009;50(suppl):S287–S292.
    1. Gajera CR, Emich H, Lioubinski O, et al. LRP2 in ependymal cells regulates BMP signaling in the adult neurogenic niche. J Cell Sci. 2010;123(11):1922–1930.
    1. Pastor P, Roe CM, Villegas A, et al. Apolipoprotein Eepsilon4 modifies Alzheimer’s disease onset in an E280A PS1 kindred. Ann Neurol. 2003;54(2):163–169.
    1. Vélez JI, Lopera F, Sepulveda-Falla D, et al. APOE*E2 allele delays age of onset in PSEN1 E280A Alzheimer’s disease. Mol Psychiatry. 2015 Dec 1; Epub.
    1. Castellano JM, Kim J, Stewart FR, et al. Human apoE isoforms differentially regulate brain amyloid-β peptide clearance. Sci Transl Med. 2011;3(89):89ra57.
    1. Kim J, Basak JM, Holtzman DM. The role of apolipoprotein E in Alzheimer’s disease. Neuron. 2009;63(3):287–303.
    1. Bales KR, Liu F, Wu S, et al. Human APOE isoform-dependent effects on brain β-amyloid levels in PDAPP transgenic mice. J Neurosci. 2009;29(21):6771–6779.
    1. Kok E, Haikonen S, Luoto T, et al. Apolipoprotein E–dependent accumulation of Alzheimer disease–related lesions begins in middle age. Ann Neurol. 2009;65(6):650–657.
    1. Polvikoski T, Sulkava R, Haltia M, et al. Apolipoprotein E, dementia, and cortical deposition of beta-amyloid protein. N Engl J Med. 1995;333(19):1242–1247.
    1. Dorey E, Chang N, Liu QY, Yang Z, Zhang W. Apolipoprotein E, amyloid-beta, and neuroinflammation in Alzheimer’s disease. Neurosci Bull. 2014;30(2):317–330.
    1. Han MR, Schellenberg GD, Wang LS, Alzheimer’s Disease Neuroimaging Initiative Genome-wide association reveals genetic effects on human Aβ42 and τ protein levels in cerebrospinal fluids: a case control study. BMC Neurol. 2010;10:90.
    1. Chiang GC, Insel PS, Tosun D, et al. Alzheimer’s Disease Neuroimaging Initiative Hippocampal atrophy rates and CSF biomarkers in elderly APOE2 normal subjects. Neurology. 2010;75(22):1976–1981.
    1. LaDu MJ, Falduto MT, Manelli AM, Reardon CA, Getz GS, Frail DE. Isoform-specific binding of apolipoprotein E to beta-amyloid. J Biol Chem. 1994;269(38):23403–23406.
    1. Poirier J. Apolipoprotein E and Alzheimer’s disease. A role in amyloid catabolism. Ann N Y Acad Sci. 2000;924:81–90.
    1. Lu PH, Thompson PM, Leow A, et al. Apolipoprotein E genotype is associated with temporal and hippocampal atrophy rates in healthy elderly adults: a tensor-based morphometry study. J Alzheimers Dis. 2011;23(3):433–442.
    1. Potkin SG, Guffanti G, Lakatos A, et al. Alzheimer’s Disease Neuroimaging Initiative Hippocampal atrophy as a quantitative trait in a genome-wide association study identifying novel susceptibility genes for Alzheimer’s disease. PLoS One. 2009;4(8):e6501.
    1. Ramanan VK, Risacher SL, Nho K, et al. Alzheimer’s Disease Neuroimaging Initiative APOE and BCHE as modulators of cerebral amyloid deposition: a florbetapir PET genome-wide association study. Mol Psychiatry. 2014;19(3):351–357.
    1. Yates PA, Desmond PM, Phal PM, et al. AIBL Research Group Incidence of cerebral microbleeds in preclinical Alzheimer disease. Neurology. 2014;82(14):1266–1273.
    1. Lambert JC, Heath S, Even G, et al. Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer’s disease. Nat Genet. 2009;41(10):1094–1099.
    1. Nuutinen T, Suuronen T, Kauppinen A, Salminen A. Clusterin: a forgotten player in Alzheimer’s disease. Brain Res Rev. 2009;61(2):89–104.
    1. Jones SE, Jomary C. Clusterin. Int J Biochem Cell Biol. 2002;34(5):427–431.
    1. Rosenberg ME, Silkensen J. Clusterin: physiologic and pathophysiologic considerations. Int J Biochem Cell Biol. 1995;27(7):633–645.
    1. Lidström AM, Bogdanovic N, Hesse C, Volkman I, Davidsson P, Blennow K. Clusterin (apolipoprotein J) protein levels are increased in hippocampus and in frontal cortex in Alzheimer’s disease. Exp Neurol. 1998;154(2):511–521.
    1. Schrijvers EM, Koudstaal PJ, Hofman A, Breteler MM. Plasma clusterin and the risk of Alzheimer disease. JAMA. 2011;305(13):1322–1326.
    1. Karch CM, Jeng AT, Nowotny P, Cady J, Cruchaga C, Goate AM. Expression of novel Alzheimer’s disease risk genes in control and Alzheimer’s disease brains. PLoS One. 2012;7(11):e50976.
    1. Deming Y, Xia J, Cai Y, et al. Alzheimer’s Disease Neuroimaging Initiative (ADNI) A potential endophenotype for Alzheimer’s disease: cerebrospinal fluid clusterin. Neurobiol Aging. 2016;37:208.e1–208.e9.
    1. Hollingworth P, Harold D, Sims R, et al. Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer’s disease. Nat Genet. 2011;43(5):429–435.
    1. Kim WS, Guillemin GJ, Glaros EN, Lim CK, Garner B. Quantitation of ATP-binding cassette subfamily-A transporter gene expression in primary human brain cells. Neuroreport. 2006;17(9):891–896.
    1. Holton P, Ryten M, Nalls M, et al. Initial assessment of the pathogenic mechanisms of the recently identified Alzheimer risk Loci. Ann Hum Genet. 2013;77(2):85–105.
    1. Reitz C, Jun G, Naj A, et al. Alzheimer Disease Genetics Consortium Variants in the ATP-binding cassette transporter (ABCA7), apolipoprotein E∈4, and the risk of late-onset Alzheimer disease in African Americans. JAMA. 2013;309(14):1483–1492.
    1. Kim WS, Li H, Ruberu K, et al. Deletion of Abca7 increases cerebral amyloid-β accumulation in the J20 mouse model of Alzheimer’s disease. J Neurosci. 2013;33(10):4387–4394.
    1. Chan SL, Kim WS, Kwok JB, et al. ATP-binding cassette transporter A7 regulates processing of amyloid precursor protein in vitro. J Neurochem. 2008;106(2):793–804.
    1. Steinberg S, Stefansson H, Jonsson T, et al. Loss-of-function variants in ABCA7 confer risk of Alzheimer’s disease. Nat Genet. 2015;47(5):445–447.
    1. Andersen OM, Reiche J, Schmidt V, et al. Neuronal sorting protein-related receptor sorLA/LR11 regulates processing of the amyloid precursor protein. Proc Natl Acad Sci U S A. 2005;102(38):13461–13466.
    1. Fjorback AW, Seaman M, Gustafsen C, et al. Retromer binds the FANSHY sorting motif in SorLA to regulate amyloid precursor protein sorting and processing. J Neurosci. 2012;32(4):1467–1480.
    1. Gustafsen C, Glerup S, Pallesen LT, et al. Sortilin and SorLA display distinct roles in processing and trafficking of amyloid precursor protein. J Neurosci. 2013;33(1):64–71.
    1. Rogaeva E, Meng Y, Lee JH, et al. The neuronal sortilin-related receptor SORL1 is genetically associated with Alzheimer disease. Nat Genet. 2007;39(2):168–177.
    1. Tsolakidou A, Alexopoulos P, Guo LH, et al. Beta-Site amyloid precursor protein-cleaving enzyme 1 activity is related to cerebrospinal fluid concentrations of sortilin-related receptor with A-type repeats, soluble amyloid precursor protein, and tau. Alzheimers Dement. 2013;9(4):386–391.
    1. Offe K, Dodson SE, Shoemaker JT, et al. The lipoprotein receptor LR11 regulates amyloid beta production and amyloid precursor protein traffic in endosomal compartments. J Neurosci. 2006;26(5):1596–1603.
    1. Capsoni S, Carlo AS, Vignone D, et al. SorLA deficiency dissects amyloid pathology from tau and cholinergic neurodegeneration in a mouse model of Alzheimer’s disease. J Alzheimers Dis. 2013;33(2):357–371.
    1. Lee JH, Barral S, Reitz C. The neuronal sortilin-related receptor gene SORL1 and late-onset Alzheimer’s disease. Curr Neurol Neurosci Rep. 2008;8(5):384–391.
    1. Reitz C, Cheng R, Rogaeva E, et al. Genetic and Environmental Risk in Alzheimer Disease 1 Consortium Meta-analysis of the association between variants in SORL1 and Alzheimer disease. Arch Neurol. 2011;68(1):99–106.
    1. Cuenco KT, Lunetta KL, Baldwin CT, et al. Association of distinct variants in SORL1 with cerebrovascular and neurodegenerative changes related to Alzheimer disease. Arch Neurol. 2008;65(12):1640–1648.
    1. De Strooper B, Annaert W. Proteolytic processing and cell biological functions of the amyloid precursor protein. J Cell Sci. 2000;113(pt 11):1857–1870.
    1. Wang Z, Lei H, Zheng M, Li Y, Cui Y, Hao F. Meta-analysis of the Association between Alzheimer Disease and Variants in GAB2, PICALM, and SORL1. Mol Neurobiol. 2015 Nov 27; Epub.
    1. Wilson JG, Andriopoulos NA, Fearon DT. CR1 and the cell membrane proteins that bind C3 and C4. A basic and clinical review. Immunol Res. 1987;6(3):192–209.
    1. Khera R, Das N. Complement Receptor 1: disease associations and therapeutic implications. Mol Immunol. 2009;46(5):761–772.
    1. Bonifati DM, Kishore U. Role of complement in neurodegeneration and neuroinflammation. Mol Immunol. 2007;44(5):999–1010.
    1. Kok EH, Luoto T, Haikonen S, Goebeler S, Haapasalo H, Karhunen PJ. CLU, CR1 and PICALM genes associate with Alzheimer’s-related senile plaques. Alzheimers Res Ther. 2011;3(2):12.
    1. Bralten J, Franke B, Arias-Vasquez A, et al. CR1 genotype is associated with entorhinal cortex volume in young healthy adults. Neurobiol Aging. 2011;32(11):2106.e7–2106.e11.
    1. Brouwers N, Van Cauwenberghe C, Engelborghs S, et al. Alzheimer risk associated with a copy number variation in the complement receptor 1 increasing C3b/C4b binding sites. Mol Psychiatry. 2012;17(2):223–233.
    1. Biffi A, Shulman JM, Jagiella JM, et al. Genetic variation at CR1 increases risk of cerebral amyloid angiopathy. Neurology. 2012;78(5):334–341.
    1. Jandus C, Simon HU, von Gunten S. Targeting Siglecs – a novel pharmacological strategy for immuno- and glycotherapy. Biochem Pharmacol. 2011;82(4):323–332.
    1. Tateno H, Li H, Schur MJ, et al. Distinct endocytic mechanisms of CD22 (Siglec-2) and Siglec-F reflect roles in cell signaling and innate immunity. Mol Cell Biol. 2007;27(16):5699–5710.
    1. Griciuc A, Serrano-Pozo A, Parrado AR, et al. Alzheimer’s disease risk gene CD33 inhibits microglial uptake of amyloid beta. Neuron. 2013;78(4):631–643.
    1. Bradshaw EM, Chibnik LB, Keenan BT, et al. CD33 Alzheimer’s disease locus: altered monocyte function and amyloid biology. Nat Neurosci. 2013;16(7):848–850.
    1. Zuccolo J, Deng L, Unruh TL, et al. Expression of MS4A and TMEM176 genes in human B lymphocytes. Front Immunol. 2013;4:195.
    1. Antunez C, Boada M, Gonzalez-Perez A, et al. Alzheimer’s Disease Neuroimaging Initiative The membrane-spanning 4-domains, subfamily A (MS4A) gene cluster contains a common variant associated with Alzheimer’s disease. Genome Med. 2011;3(5):33.
    1. Jonsson T, Stefansson H, Steinberg S, et al. Variant of TREM2 associated with the risk of Alzheimer’s disease. N Engl J Med. 2013;368(2):107–116.
    1. Guerreiro R, Wojtas A, Bras J, et al. Alzheimer Genetic Analysis Group TREM2 variants in Alzheimer’s disease. N Engl J Med. 2013;368(2):117–127.
    1. Jin SC, Benitez BA, Karch CM, et al. Coding variants in TREM2 increase risk for Alzheimer’s disease. Hum Mol Genet. 2014;23(21):5838–5846.
    1. Guerreiro RJ, Lohmann E, Brás JM, et al. Using exome sequencing to reveal mutations in TREM2 presenting as a frontotemporal dementia-like syndrome without bone involvement. JAMA Neurol. 2013;70(1):78–84.
    1. Paloneva J, Kestilä M, Wu J, et al. Loss-of-function mutations in TYROBP (DAP12) result in a presenile dementia with bone cysts. Nat Genet. 2000;25(3):357–361.
    1. Paloneva J, Manninen T, Christman G, et al. Mutations in two genes encoding different subunits of a receptor signaling complex result in an identical disease phenotype. Am J Hum Genet. 2002;71(3):656–662.
    1. Rayaprolu S, Mullen B, Baker M, et al. TREM2 in neurodegeneration: evidence for association of the p.R47H variant with frontotemporal dementia and Parkinson’s disease. Mol Neurodegener. 2013;8:19.
    1. Cady J, Koval ED, Benitez BA, et al. TREM2 variant p.R47H as a risk factor for sporadic amyotrophic lateral sclerosis. JAMA Neurol. 2014;71(4):449–453.
    1. Cruchaga C, Kauwe JS, Harari O, et al. GERAD Consortium. Alzheimer’s Disease Neuroimaging Initiative (ADNI) Alzheimer Disease Genetic Consortium (ADGC) GWAS of cerebrospinal fluid tau levels identifies risk variants for Alzheimer’s disease. Neuron. 2013;78(2):256–268.
    1. Rajagopalan P, Hibar DP, Thompson PM. TREM2 and neurodegenerative disease. N Engl J Med. 2013;369(16):1565–1567.
    1. Pant S, Sharma M, Patel K, Caplan S, Carr CM, Grant BD. AMPH-1/Amphiphysin/Bin1 functions with RME-1/Ehd1 in endocytic recycling. Nat Cell Biol. 2009;11(12):1399–1410.
    1. Tan MS, Yu JT, Tan L. Bridging integrator 1 (BIN1): form, function, and Alzheimer’s disease. Trends Mol Med. 2013;19(10):594–603.
    1. Kamboh MI, Demirci FY, Wang X, et al. Genome-wide association study of Alzheimer’s disease. Transl Psychiatry. 2012;2:e117.
    1. Biffi A, Anderson CD, Desikan RS, et al. Genetic variation and neuroimaging measures in Alzheimer disease. Arch Neurol. 2010;67(6):677–685.
    1. Chapuis J, Hansmannel F, Gistelinck M, et al. Increased expression of BIN1 mediates Alzheimer genetic risk by modulating tau pathology. Mol Psychiatry. 2013;18(11):1225–1234.
    1. Monzo P, Gauthier NC, Keslair F, et al. Clues to CD2-associated protein involvement in cytokinesis. Mol Biol Cell. 2005;16(6):2891–2902.
    1. Shulman JM, Chen K, Keenan BT, et al. Genetic susceptibility for Alzheimer disease neuritic plaque pathology. JAMA Neurol. 2013;70(9):1150–1157.
    1. Liao F, Jiang H, Srivatsan S, et al. Effects of CD2-associated protein deficiency on amyloid-β in neuroblastoma cells and in an APP transgenic mouse model. Mol Neurodegener. 2015;10:12.
    1. Chen H, Wu G, Jiang Y, et al. Analyzing 54,936 samples supports the association between CD2AP rs9349407 polymorphism and Alzheimer’s disease susceptibility. Mol Neurobiol. 2015;52(1):1–7.
    1. Xiao Q, Gil SC, Yan P, et al. Role of phosphatidylinositol clathrin assembly lymphoid-myeloid leukemia (PICALM) in intracellular amyloid precursor protein (APP) processing and amyloid plaque pathogenesis. J Biol Chem. 2012;287(25):21279–21289.
    1. Melville SA, Buros J, Parrado AR, et al. Alzheimer’s Disease Neuroimaging Initiative Multiple loci influencing hippocampal degeneration identified by genome scan. Ann Neurol. 2012;72(1):65–75.
    1. Schjeide BM, Schnack C, Lambert JC, et al. The role of clusterin, complement receptor 1, and phosphatidylinositol binding clathrin assembly protein in Alzheimer disease risk and cerebrospinal fluid biomarker levels. Arch Gen Psychiatry. 2011;68(2):207–213.
    1. Baig S, Joseph SA, Tayler H, et al. Distribution and expression of picalm in Alzheimer disease. J Neuropathol Exp Neurol. 2010;69(10):1071–1077.
    1. Zhao Z, Sagare AP, Ma Q, et al. Central role for PICALM in amyloid-β blood-brain barrier transcytosis and clearance. Nat Neurosci. 2015;18(7):978–987.
    1. Moreau K, Fleming A, Imarisio S, et al. PICALM modulates autophagy activity and tau accumulation. Nat Commun. 2014;5:4998.
    1. Treusch S, Hamamichi S, Goodman JL, et al. Functional links between Abeta toxicity, endocytic trafficking, and Alzheimer’s disease risk factors in yeast. Science. 2011;334(6060):1241–1245.
    1. Morgen K, Ramirez A, Frölich L, et al. Genetic interaction of PICALM and APOE is associated with brain atrophy and cognitive impairment in Alzheimer’s disease. Alzheimers Dement. 2014;10(5 suppl):S269–S276.
    1. Lai KO, Ip NY. Synapse development and plasticity: roles of ephrin/Eph receptor signaling. Curr Opin Neurobiol. 2009;19(3):275–283.
    1. Yamazaki T, Masuda J, Omori T, Usui R, Akiyama H, Maru Y. EphA1 interacts with integrin-linked kinase and regulates cell morphology and motility. J Cell Sci. 2009;122(pt 2):243–255.
    1. Wang HF, Tan L, Hao XK, et al. Effect of EPHA1 genetic variation on cerebrospinal fluid and neuroimaging biomarkers in healthy, mild cognitive impairment and Alzheimer’s disease cohorts. J Alzheimers Dis. 2015;44(1):115–123.
    1. Ruiz A, Heilmann S, Becker T, et al. Follow-up of loci from the International Genomics of Alzheimer’s Disease Project identifies TRIP4 as a novel susceptibility gene. Transl Psychiatry. 2014;4:e358.
    1. Guerreiro R, Brás J, Hardy J. SnapShot: genetics of Alzheimer’s disease. Cell. 2013;155(4):968–968.e1.
    1. Lang HL, Jacobsen H, Ikemizu S, et al. A functional and structural basis for TCR cross-reactivity in multiple sclerosis. Nat Immunol. 2002;3(10):940–943.
    1. Hamza TH, Zabetian CP, Tenesa A, et al. Common genetic variation in the HLA region is associated with late-onset sporadic Parkinson’s disease. Nat Genet. 2010;42(9):781–785.
    1. Chen Z, Shojaee S, Buchner M, et al. Signalling thresholds and negative B-cell selection in acute lymphoblastic leukaemia. Nature. 2015;521(7552):357–361.
    1. Viernes DR, Choi LB, Kerr WG, Chisholm JD. Discovery and development of small molecule SHIP phosphatase modulators. Med Res Rev. 2014;34(4):795–824.
    1. Nowakowska BA, Obersztyn E, Szymanska K, et al. Severe mental retardation, seizures, and hypotonia due to deletions of MEF2C. Am J Med Genet B Neuropsychiatr Genet. 2010;153b(5):1042–1051.
    1. Clark RI, Tan SW, Péan CB, et al. MEF2 is an in vivo immune-metabolic switch. Cell. 2013;155(2):435–447.
    1. Singh MK, Dadke D, Nicolas E, et al. A novel Cas family member, HEPL, regulates FAK and cell spreading. Mol Biol Cell. 2008;19(4):1627–1636.
    1. Beecham GW, Hamilton K, Naj AC, et al. Genome-wide association meta-analysis of neuropathologic features of Alzheimer’s disease and related dementias. PLoS Genet. 2014;10(9):e1004606.
    1. Rosenthal SL, Barmada MM, Wang X, Demirci FY, Kamboh MI. Connecting the dots: potential of data integration to identify regulatory SNPs in late-onset Alzheimer’s disease GWAS findings. PLoS One. 2014;9(4):e95152.
    1. Beck TN, Nicolas E, Kopp MC, Golemis EA. Adaptors for disorders of the brain? The cancer signaling proteins NEDD9, CASS4, and PTK2B in Alzheimer’s disease. Oncoscience. 2014;1(7):486–503.
    1. Alier KA, Morris BJ. Divergent regulation of Pyk2/CAKbeta phosphorylation by Ca2+ and cAMP in the hippocampus. Biochim Biophys Acta. 2005;1745(3):342–349.
    1. Jiao B, Liu X, Zhou L. Polygenic analysis of late-onset Alzheimer’s disease from mainland China. PLoS One. 2015;10(12):e0144898.
    1. Kaufman AC, Salazar SV, Haas LT, et al. Fyn inhibition rescues established memory and synapse loss in Alzheimer mice. Ann Neurol. 2015;77(6):953–971.
    1. Kim SH, Fountoulakis M, Cairns NJ, Lubec G. Human brain nucleoside diphosphate kinase activity is decreased in Alzheimer’s disease and Down syndrome. Biochem Biophys Res Commun. 2002;296(4):970–975.
    1. Liu Y, Yu JT, Wang HF, et al. Association between NME8 locus polymorphism and cognitive decline, cerebrospinal fluid and neuroimaging biomarkers in Alzheimer’s disease. PLoS One. 2014;9(12):e114777.
    1. Duriez B, Duquesnoy P, Escudier E, et al. A common variant in combination with a nonsense mutation in a member of the thioredoxin family causes primary ciliary dyskinesia. Proc Natl Acad Sci U S A. 2007;104:3336–3341.
    1. Shi D, Nakamura T, Nakajima M, et al. Association of single-nucleotide polymorphisms in RHOB and TXNDC3 with knee osteoarthritis susceptibility: two case-control studies in East Asian populations and a meta-analysis. Arthritis Res Ther. 2008;10(3):R54.
    1. He F, Umehara T, Saito K, et al. Structural insight into the zinc finger CW domain as a histone modification reader. Structure. 2010;18(9):1127–1139.
    1. Allen M, Kachadoorian M, Carrasquillo MM, et al. Late-onset Alzheimer disease risk variants mark brain regulatory loci. Neurol Genet. 2015;1(2):e15.
    1. Beisang D, Reilly C, Bohjanen PR. Alternative polyadenylation regulates CELF1/CUGBP1 target transcripts following T cell activation. Gene. 2014;550(1):93–100.
    1. House RP, Talwar S, Hazard ES, Hill EG, Palanisamy V. RNA-binding protein CELF1 promotes tumor growth and alters gene expression in oral squamous cell carcinoma. Oncotarget. 2015;6(41):43620–43634.
    1. Xia L, Sun C, Li Q, et al. CELF1 is up-regulated in glioma and promotes glioma cell proliferation by suppression of CDKN1B. Int J Biol Sci. 2015;11(11):1314–1324.
    1. Kuyumcu-Martinez NM, Wang GS, Cooper TA. Increased steady-state levels of CUGBP1 in myotonic dystrophy 1 are due to PKC-mediated hyperphosphorylation. Mol Cell. 2007;28(1):68–78.
    1. Shulman JM, Imboywa S, Giagtzoglou N, et al. Functional screening in Drosophila identifies Alzheimer’s disease susceptibility genes and implicates Tau-mediated mechanisms. Hum Mol Genet. 2014;23(4):870–877.
    1. Kahner BN, Kato H, Banno A, Ginsberg MH, Shattil SJ, Ye F. Kindlins, integrin activation and the regulation of talin recruitment to αIIbβ3. PLoS One. 2012;7(3):e34056.
    1. Zhan J, Zhu X, Guo Y, et al. Opposite role of Kindlin-1 and Kindlin-2 in lung cancers. PLoS One. 2012;7(11):e50313.
    1. Yu Y, Wu J, Guan L, et al. Kindlin 2 promotes breast cancer invasion via epigenetic silencing of the microRNA200 gene family. Int J Cancer. 2013;133(6):1368–1379.
    1. Shen Z, Ye Y, Kauttu T, et al. Novel focal adhesion protein kindlin-2 promotes the invasion of gastric cancer cells through phosphorylation of integrin beta1 and beta3. J Surg Oncol. 2013;108(2):106–112.
    1. Dowling JJ, Vreede AP, Kim S, Golden J, Feldman EL. Kindlin-2 is required for myocyte elongation and is essential for myogenesis. BMC Cell Biol. 2008;9:36.
    1. Pluskota E, Dowling JJ, Gordon N, et al. The integrin coactivator kindlin-2 plays a critical role in angiogenesis in mice and zebrafish. Blood. 2011;117(18):4978–4987.
    1. Larsson M, Duffy DL, Zhu G, et al. GWAS findings for human iris patterns: associations with variants in genes that influence normal neuronal pattern development. Am J Hum Genet. 2011;89(2):334–343.
    1. Han J, Kraft P, Nan H, et al. A genome-wide association study identifies novel alleles associated with hair color and skin pigmentation. PLoS Genet. 2008;4(5):e1000074.
    1. Yu L, Chibnik LB, Srivastava GP, et al. Association of Brain DNA methylation in SORL1, ABCA7, HLA-DRB5, SLC24A4, and BIN1 with pathological diagnosis of Alzheimer disease. JAMA Neurol. 2015;72(1):15–24.
    1. Kajiho H, Saito K, Tsujita K, et al. RIN3: a novel Rab5 GEF interacting with amphiphysin II involved in the early endocytic pathway. J Cell Sci. 2003;116(20):4159–4168.
    1. Kraja AT, Borecki IB, Tsai MY, et al. Genetic analysis of 16 NMR-lipoprotein fractions in humans, the GOLDN study. Lipids. 2013;48(2):155–165.
    1. Zhang M, Xue A, Shen Y, et al. Mutations of desmoglein-2 in sudden death from arrhythmogenic right ventricular cardiomyopathy and sudden unexplained death. Forensic Sci Int. 2015;255:85–88.
    1. Ramani VC, Hennings L, Haun RS. Desmoglein 2 is a substrate of kallikrein 7 in pancreatic cancer. BMC Cancer. 2008;8:373.
    1. Kurzen H, Munzing I, Hartschuh W. Expression of desmosomal proteins in squamous cell carcinomas of the skin. J Cutan Pathol. 2003;30(10):621–630.
    1. Osisami M, Ali W, Frohman MA. A role for phospholipase D3 in myotube formation. PLoS One. 2012;7(3):e33341.
    1. Cruchaga C, Karch CM, Jin SC, et al. Rare coding variants in the phospholipase D3 gene confer risk for Alzheimer’s disease. Nature. 2014;505(7484):550–554.
    1. Satoh J, Kino Y, Yamamoto Y, et al. PLD3 is accumulated on neuritic plaques in Alzheimer’s disease brains. Alzheimers Res Ther. 2014;6(9):70.
    1. Wetzel-Smith MK, Hunkapiller J, Bhangale TR, et al. A rare mutation in UNC5C predisposes to late-onset Alzheimer’s disease and increases neuronal cell death. Nat Med. 2014;20(12):1452–1457.
    1. Jiao B, Liu X, Tang B, et al. Investigation of TREM2, PLD3, and UNC5C variants in patients with Alzheimer’s disease from mainland China. Neurobiol Aging. 2014;35(10):2422.e9–2422.e11.
    1. Hunkapiller J, Wetzel M, Bhangale T, et al. A rare coding variant alters UNC5C function and predisposes to Alzheimer’s disease. Alzheimers Dement. 2013;9(4):853.
    1. Maloney JA, Bainbridge T, Gustafson A, et al. Molecular mechanisms of Alzheimer disease protection by the A673T allele of amyloid precursor protein. J Biol Chem. 2014;289(45):30990–31000.
    1. Mengel-From J, Jeune B, Pentti T, McGue M, Christensen K, Christiansen L. The APP A673T frequency differs between Nordic countries. Neurobiol Aging. 2015;36(10):2909.e1–2909.e4.
    1. Ting SK, Chong MS, Kandiah N, et al. Absence of A673T amyloid-β precursor protein variant in Alzheimer’s disease and other neurological diseases. Neurobiol Aging. 2013;34(10):2441.e7–2441.e8.
    1. Logue MW, Schu M, Vardarajan BN, et al. Alzheimer Disease Genetics Consortium. Alzheimer Disease Genetics Consortium Two rare AKAP9 variants are associated with Alzheimer’s disease in African Americans. Alzheimers Dement. 2014;10(6):609.e11–618.e11.
    1. Venkatesh D, Mruk D, Herter JM, et al. AKAP9, a regulator of microtubule dynamics, contributes to blood-testis barrier function. Am J Pathol. 2016;186(2):270–284.
    1. de Villiers CP, van der Merwe L, Crotti L, et al. AKAP9 is a genetic modifier of congenital long-QT syndrome type 1. Circ Cardiovasc Genet. 2014;7(5):599–606.
    1. Kim M, Suh J, Romano D, et al. Potential late-onset Alzheimer’s disease-associated mutations in the ADAM10 gene attenuate α-secretase activity. Hum Mol Genet. 2009;18(20):3987–3996.
    1. Cai G, Atzmon G, Naj AC, et al. Evidence against a role for rare ADAM10 mutations in sporadic Alzheimer disease. Neurobiol Aging. 2012;33(2):416.e3–417.e3.
    1. Suh J, Choi SH, Romano DM, et al. ADAM10 missense mutations potentiate β-amyloid accumulation by impairing prodomain chaperone function. Neuron. 2013;80(2):385–401.
    1. Morris GP, Clark IA, Vissel B. Inconsistencies and controversies surrounding the amyloid hypothesis of Alzheimer’s disease. Acta Neuropathol Commun. 2014;2:135.
    1. Mullane K, Williams M. Alzheimer’s therapeutics: continued clinical failures question the validity of the amyloid hypothesis-but what lies beyond? Biochem Pharmacol. 2013;85(3):289–305.

Source: PubMed

스폰서 및 공동 작업자

건강 상태

약물 개입

3
구독하다